<DOC>
	<DOC>NCT01847222</DOC>
	<brief_summary>Safety assessment of SANGUINATE™ in Healthy Volunteers.</brief_summary>
	<brief_title>An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.</brief_title>
	<detailed_description>Safety and Pharmacokinetic assessment in ascending doses of SANGUINATE™ in Healthy Volunteers.</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Male Volunteers; Age ≥18 years and ≤45 years; BMI ≥20 ≤30 kg/m² No clinically significant screening observations Female volunteers; Any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, chronic hepatic disease or any other disease which in the judgment of the Investigator would interfere with the study or confound the results; History of allergy or major allergic reactions considered to be clinically significant by the Investigator; Any screening assessment determined to be clinically significant by the Investigator; Donate blood within 60 days of screening or otherwise experienced blood loss &gt;250 mL within the same period;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>